Effects of abciximab and tirofiban on vitronectin receptors in human endothelial and smooth muscle cells

European Journal of Pharmacology

Volumn 390, Issue 1-2, 2000, Pages 75-87

  Kintscher, Ulrich ^a   Kappert, Kai ^a   Schmidt, Gunther ^a   Doerr, Gesine ^a   Grill, Matthias ^a   Wollert Wulf, Brigitte ^a   Graefe, Michael ^a   Fleck, Eckart ^a   Graf, Kristof ^a  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

Author keywords

Endothelial cell; Glycoprotein IIb IIIa inhibitor; Human; Integrin; Smooth muscle cell; Vascular; Vitronectin

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST; INTEGRIN; PROTEIN ANTIBODY; RECEPTOR SUBTYPE; TIROFIBAN; VITRONECTIN RECEPTOR;

ARTERY MUSCLE; ARTICLE; CELL ADHESION; CELL CULTURE; CELL INTERACTION; CELL SPREADING; CELL TYPE; CONTROLLED STUDY; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; ILIAC ARTERY; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; UMBILICAL VEIN;

ANTIBODIES, MONOCLONAL; CELL ADHESION; ENDOTHELIUM, VASCULAR; FIBRINOLYTIC AGENTS; FLOW CYTOMETRY; HUMANS; ILIAC ARTERY; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOHISTOCHEMISTRY; INTEGRINS; MUSCLE, SMOOTH, VASCULAR; OLIGOPEPTIDES; RECEPTORS, VITRONECTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TYROSINE; UMBILICAL VEINS; VITRONECTIN;

EID: 0034712020     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00912-7     Document Type: Article

References (50)

1. Ashizawa N., Graf K., Do Y.S., Nunohiro T., Giachelli C.M., Meehan W.P., Tuan T.L., Hsueh W.A. Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. J. Clin. Invest. 98:1996;2218-2227.
2. Bilato C., Curto K.A., Monticone R.E., Pauly R.R., White A.J., Crow M.T. The inhibition of vascular smooth muscle cell migration by peptide and antibody antagonists of the alphavbeta3 integrin complex is reversed by activated calcium/calmodulin-dependent protein kinase II. J. Clin. Invest. 100:1997;693-704.
3. Brown S.L., Lundgren C.H., Nordt T., Fujii S. Stimulation of migration of human aortic smooth muscle cells by vitronectin: implications for atherosclerosis. Cardiovasc. Res. 28:1994;1815-1820.
4. Choi E.T., Engel L., Callow A.D., Sun S., Trachtenberg J., Santoro S., Ryan U.S. Inhibition of neointimal hyperplasia by blocking alpha V beta 3 integrin with a small peptide antagonist GpenGRGDSPCA. J. Vasc. Surg. 19:1994;125-134.
5. Clyman R.I., Mauray F., Kramer R.H. Beta 1 and beta 3 integrins have different roles in the adhesion and migration of vascular smooth muscle cells on extracellular matrix. Exp. Cell. Res. 200:1992;272-284.
6. Coller B.S., Cheresh D.A., Asch E., Seligsohn U. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel. Blood. 77:1991;75-83.
7. Conforti G., Dominguez-Jimenez C., Zanetti A., Gimbrone M.A. Jr., Cremona O., Marchisio P.C., Dejana E. Human endothelial cells express integrin receptors on the luminal aspect of their membrane. Blood. 80:1992;437-446.
8. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N. Engl. J. Med. 330:1994;956-961.
9. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N. Engl. J. Med. 336:1997;1689-1696.
10. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 352:1998;87-92.
11. Giachelli C.M., Liaw L., Murry C.E., Schwartz S.M., Almeida M. Osteopontin expression in cardiovascular diseases. Ann. N. Y. Acad. Sci. 760:1995;109-126.
12. Goetze S., Xi X.P., Kawano H., Gotlibowski T., Fleck E., Hsueh W.A., Law R.E. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 33:1999;798-806.
13. Graefe M., Bossaller C., Graf K., Auch-Schwelk W., Baumgarten C.R., Hildebrandt A., Fleck E. Effect of angiotensin-converting-enzyme inhibition on bradykinin metabolism by vascular endothelial cells. Am. J. Physiol. 264:1993;H1493-H1497.
14. Graf K., Meehan W.P., Chen J.Z., Law R.E., Fleck E., Hsueh W.A. Upregulation of αv, β3 and β5-integrin mRNA during neointima formation in the rat aorta after balloon injury. Circulation. 94(I-41):1996;230. Abstract.
15. Hall S.E., Savill J.S., Henson P.M., Haslett C. Apoptotic neutrophils are phagocytosed by fibroblasts with participation of the fibroblast vitronectin receptor and involvement of a mannose/fucose-specific lectin. J. Immunol. 153:1994;3218-3227.
16. Holmsen H. Platelet secretion and energy metabolism. Colman R.W., Hirsh J., Marder V.J., Salzman E.W. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 1994;524-545 Lippincott, J.B. Philadelphia.
17. Hoshiga M., Alpers C.E., Smith L.L., Giachelli C.M., Schwartz S.M. Alpha-v beta-3 integrin expression in normal and atherosclerotic artery. Circ. Res. 77:1995;1129-1135.
18. Hynes R.O. Integrins: a family of cell surface receptors. Cell. 48:1987;549-554.
19. Keularts I.M., Beguin S., de Zwaan C., Hemker H.C. Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients. Thromb. Haemostasis. 80:1998;370-371.
20. Liaw L., Almeida M., Hart C.E., Schwartz S.M., Giachelli C.M. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ. Res. 74:1994;214-224.
21. Liaw L., Lindner V., Schwartz S.M., Chambers A.F., Giachelli C.M. Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. Circ. Res. 77:1995;665-672.
22. Liaw L., Skinner M.P., Raines E.W., Ross R., Cheresh D.A., Schwartz S.M., Giachelli C.M. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J. Clin. Invest. 95:1995;713-724.
23. Lincoff A.M., Korngold S. An overview of platelet GP IIb/IIIa receptor antagonists trials. Eur. Heart J. (Suppl. E):1999;E18-E26.
24. Lincoff A.M., Tcheng J.E., Califf R.M., Kereiakes D.J., Kelly T.A., Timmis G.C., Kleiman N.S., Booth J.E., Balog C., Cabot C.F., Anderson K.M., Weisman H.F., Topol E.J. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation. 99:1999;1951-1958.
25. Lupu F., Bergonzelli G.E., Heim D.A., Cousin E., Genton C.Y., Bachmann F., Kruithof E.K. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler. Thromb. 13:1993;1090-1100.
26. Matsuno H., Stassen J.M., Vermylen J., Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation. 90:1994;2203-2206.
27. Nakada M.T., Jordan R.E., Knight D.M. Abciximab (ReoPro, chimeric 7E3 Fab) cross-specificity with avb3-integrin receptors: a potential mechanism for the prevention of restenosis. J. Am. Coll. Cardiol. 28:1997;243. Abstract.
28. Panda D., Kundu G.C., Lee B.I., Peri A., Fohl D., Chackalaparampil I., Mukherjee B.B., Li X.D., Mukherjee D.C., Seides S., Rosenberg J., Stark K., Mukherjee A.B. Potential roles of osteopontin and alphaVbeta3 integrin in the development of coronary artery restenosis after angioplasty. Proc. Natl. Acad. Sci. U. S. A. 94:1997;9308-9313.
29. Peerlinck K., De Lepeleire I., Goldberg M., Farrell D., Barrett J., Hand E., Panebianco D., Deckmyn H., Vermylen J., Arnout J. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation. 88:1993;1512-1517.
30. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N. Engl. J. Med. 338:1998;1498-1505.
31. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N. Engl. J. Med. 338:1998;1488-1497.
32. Regitz-Zagrosek V., Fielitz J., Hummel M., Hildebrandt A.G., Hetzer R., Fleck E. Decreased expression of ventricular angiotensin receptor type 1 mRNA after human heart transplantation. J. Mol. Med. 74:1996;777-782.
33. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized efficacy study of tirofiban for outcomes and restenosis. Circulation. 96:1997;1445-1453.
34. Reverter J.C., Beguin S., Kessels H., Kumar R., Hemker H.C., Coller B.S. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis" J. Clin. Invest. 98:1996;863-874.
35. Ross R., Kariya B. Morphogenesis of vascular smooth muscle in atherosclerosis and cell structure. Bohr D.F., Somiyo A.P., Sparks H.Y. Handbook of Physiology: The Cardiovascular System, Section 2. 1988;69-91 American Physiology Society, Bethesda, MD.
36. Ruegg C., Yilmaz A., Bieler G., Bamat J., Chaubert P., Lejeune F.J. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat. Med. 4:1998;408-414.
37. Skinner M.P., Raines E.W., Ross R. Dynamic expression of alpha 1 beta 1 and alpha 2 beta 1 integrin receptors by human vascular smooth muscle cells. Alpha 2 beta 1 integrin is required for chemotaxis across type I collagen-coated membranes. Am. J. Pathol. 145:1994;1070-1081.
38. Slepian M.J., Massia S.E., Dehdashti B., Fritz A., Whitesell L. Beta3-integrins rather than beta1-integrins dominate integrin-matrix interactions involved in postinjury smooth muscle cell migration. Circulation. 97:1998;1818-1827.
39. Smith J.W., Vestal D.J., Irwin S.V., Burke T.A., Cheresh D.A. Purification and functional characterization of integrin alpha v beta 5. An adhesion receptor for vitronectin. J. Biol. Chem. 265:1990;11008-11013.
40. Srivatsa S.S., Fitzpatrick L.A., Tsao P.W., Reilly T.M., Holmes D.R. Jr., Schwartz R.S., Mousa S.A. Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formation. Cardiovasc. Res. 36:1997;408-428.
41. Stern M., Savill J., Haslett C. Human monocyte-derived macrophage phagocytosis of senescent eosinophils undergoing apoptosis. Mediation by alpha v beta 3/CD36/thrombospondin recognition mechanism and lack of phlogistic response. Am. J. Pathol. 149:1996;911-921.
42. Stouffer G.A., Hu Z., Sajid M., Li H., Jin G., Nakada M.T., Hanson S.R., Runge M.S. Beta3 integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells. Circulation. 97:1998;907-915.
43. Tam S.H., Sassoli P.M., Jordan R.E., Nakada M.T. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation. 98:1998;1085-1091.
44. Topol E.J., Byzova T.V., Plow E.F. Platelet GPIIb-IIIa blockers. Lancet. 353:1999;227-231.
45. Topol E.J., Califf R.M., Weisman H.F., Ellis S.G., Tcheng J.E., Worley S., Ivanhoe R., George B.S., Fintel D., Weston M., Sigmon K., Anderson K.M., Lee K.L., Willerson J.T. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet. 343:1994;881-886.
46. Van Zanten G.H., de Graaf S., Slootweg P.J., Heijnen H.F., Connolly T.M., De Groot P.G., Sixma J.J. Increased platelet deposition on atherosclerotic coronary arteries. J. Clin. Invest. 93:1994;615-632.
47. Walsh P.N., Schmaier A.H. Platelet-coagulant protein interactions. Colman R.W., Hirsh J., Marder V.J., Salzman E.W. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 1994;629-651 J.B. Lippincott, Philadelphia.
48. Wang X., Louden C., Ohlstein E.H., Stadel J.M., Gu J.L., Yue T.L. Osteopontin expression in platelet-derived growth factor-stimulated vascular smooth muscle cells and carotid artery after balloon angioplasty. Arterioscler. Thromb. Vasc. Biol. 16:1996;1365-1372.
49. Wayner E.A., Orlando R.A., Cheresh D.A. Integrins alpha v beta 3 and alpha v beta 5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface. J. Cell Biol. 113:1991;919-929.
50. Yamamoto K., Yamamoto M. Cell adhesion receptors for native and denatured type I collagens and fibronectin in rabbit arterial smooth muscle cells in culture. Exp. Cell Res. 214:1994;258-263.